4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Yanni Lv und 3 weiteren Autor:innen. Beteiligte Einrichtung: Yantai Yuhuangding Hospital, 20 Yudong Road, Yantai, Shandong Province 264099, PR China. Hauptthemen laut MEDLINE: Tamoxifen, Neuropilin-1, Drug Resistance, Neoplasm, Paclitaxel. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Objectives
Tamoxifen is an endocrine therapy for breast cancer that works by competing with estradiol for estrogen receptors, but continued use of tamoxifen by patients can lead to resistance and metastasis. Studies have shown that 4-hydroxytamoxifen (4-OH-TAM), the active product of tamoxifen, promotes the malignant biological behavior of breast cancer cells, but the mechanism is not fully understood.
Methods
We investigated the effects of 4-OH-TAM on breast cancer cell stemness, paclitaxel (PTX) resistance and metastasis. Molecular mechanism studies were used to investigate the pro-cancer effects of 4-OH-TAM. Key findings Treatment with low-dose 4-OH-TAM increased the resistance of ER-positive (MCF-7 and T47D cells) and triple-negative (4T1 and MDA-MB-231 cells) breast cancer cells to PTX. In vitro and in vivo experiments showed that 4-OH-TAM enhanced stemness in T47D and 4T1 cells by upregulating the stem cell markers CD44 and CD133. Mechanistically, 4-OH-TAM enhanced breast cancer cell stemness by upregulating estrogen-related receptor alpha (ERRα) protein expression via neuropilin-1 (NRP-1). Notably, inhibition of the NRP-1/ERRα signaling pathway reversed 4-OH-TAM-induced PTX resistance and tumor metastasis.
Conclusion
4-hydroxytamoxifen enhances stemness through the NRP/ERRα pathway to enhance breast cancer cell PTX resistance and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yantai Yuhuangding Hospital, 20 Yudong Road, Yantai, Shandong Province 264099, PR China.
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Pharmaceutical Science, 39 Science and Technology Avenue, Yantai, Shandong Province 264000, PR China.
ORCID-Profile: Lu Chen
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Lv, Y., Yu, Q., Zhang, L., & Chen, L. (2026). 4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag007
Vancouver
Lv Y, Yu Q, Zhang L, Chen L. 4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag007
BibTeX
@article{Lv2026,
author = {Lv, Yanni and Yu, Qinglong and Zhang, Li and Chen, Lu},
title = {4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag007}
}
EUVIMED